FDA approves BridgeBio Pharma's heart disease drug 'acoramidis' for treating Transthyretin amyloid cardiomyopathy

From Nasdaq: 2024-11-23 20:07:13

The FDA approved BridgeBio Pharma Inc.’s Attruby for treating Transthyretin amyloid cardiomyopathy, reducing cardiovascular death and hospitalization. Positive results from the ATTRibute-CM Phase 3 study supported the approval, showing significant benefits in patient outcomes. BridgeBio will receive a $500 million payment as part of a royalty funding agreement. The company has also applied for approval in Europe, with a decision expected in 2025, and granted commercialization rights to Bayer. Learn more about health news at rttnews.com.



Read more at Nasdaq: BridgeBio Pharma : FDA Approves Heart Disease Drug ‘acoramidis’